Helsinn Healthcare SA announces the launch of ALOXI® (palonosetron hcl) injection for the prevention of postoperative nausea and vomiting in the USA
Lugano (ots) - Helsinn's Top Management and its U.S. partner Eisai Inc. today announced the availability in the USA of ALOXI® (palonosetron hydrochloride) injection 0.075 mg for the prevention of postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. The introduction of ALOXI® for PONV ...